Results 261 to 270 of about 320,703 (320)

Pegylated interferons.

Reviews in gastroenterological disorders, 2002
Interferon therapy for chronic hepatitis C is not a cure, but it is able to decrease the viral load and may decrease the risk of complications (e.g., cirrhosis, liver failure, liver cancer). Pegylation of the interferon increases the amount of time the interferon remains in the body by increasing the size of the interferon molecule. Increasing molecule
openaire   +1 more source

Pegylated Interferon Monotherapy for Chronic Hepatitis C

Seminars in Liver Disease, 2004
Interferon (IFN) alpha-2a has been attached to a branched 40-kD PEG molecule and IFN alpha-2b to a linear 12-kD PEG molecule leading to elimination half-lives of approximately 75 and approximately 30 hours, respectively. In one pivotal trial, 531 patients with chronic hepatitis C were assigned to receive either 180 microg of pegylated IFN alpha-2a once
Jenny, Heathcote, Stefan, Zeuzem
openaire   +2 more sources

Treatment with Interferons (including Pegylated Interferons) in Patients with Hepatitis B

Seminars in Liver Disease, 2004
Studies of 4 to 6 months of treatment with interferon for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection have shown clearance of HBeAg to be higher in treated patients than it is in controls by approximately 25%. These results are considerably better than those with antiviral agents.
openaire   +2 more sources

Pegylated Interferons for the Treatment of Chronic Hepatitis B

Recent Patents on Anti-Infective Drug Discovery, 2006
Five drugs are approved for the treatment of chronic hepatitis B: conventional interferon (IFN) alfa, lamivudine, adefovir dipivoxil, pegylated interferon (peginterferon) alfa-2a and entecavir. Conventional IFN monotherapy has a narrow range of efficacy, should be administered subcutaneously and is commonly associated with adverse effects.
Chun-Jen, Liu, Jia-Horng, Kao
openaire   +2 more sources

Treatment of cirrhotic patients in the pegylated interferon era

Digestive and Liver Disease, 2004
Chronic hepatitis C is a leading cause of cirrhosis, hepatocellular carcinoma, digestive tract haemorrhage and hepatic insufficiency. The present best strategy to prevent severe complications of chronic hepatitis C is the decrease of fibrosis progression. Recently, pegylated interferon combination treatments of chronic hepatitis C have made it possibly
openaire   +2 more sources

Pegylated interferons

Journal of Drug Evaluation, 2004
Raymond D'Souza, Graham Foster
openaire   +1 more source

Emerging strategies for pegylated interferon combination therapy

Nature Clinical Practice Gastroenterology & Hepatology, 2007
Several advances afford promise for improving the management of hepatitis C virus (HCV) infection. Current therapies primarily target the immune system; the now proven ability to culture the entire virus in vitro could ultimately facilitate the identification of therapies directly targeting viral replication.
openaire   +2 more sources

Pegylation of Interferon Alfa: Structural and Pharmacokinetic Properties

Seminars in Liver Disease, 2003
The attachment of a polyethylene glycol (PEG) polymer to a protein or peptide is becoming increasingly common within the pharmaceutical industry as a way of altering the activity of the parent molecule. Significant improvements in biological activity with PEG molecules have been seen with several licensed drugs, allowing for product life cycle ...
openaire   +2 more sources

Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection

Expert Opinion on Drug Metabolism & Toxicology, 2018
A. Maughan, O. Ogbuagu
semanticscholar   +1 more source

Interferon-γ: teammate or opponent in the tumour microenvironment?

Nature Reviews Immunology, 2021
Creg J Workman, Dario A A Vignali
exaly